Dyskeratosis Congenita clinical trials
The registry lists 20 studies for Dyskeratosis Congenita across more than 10 countries. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-10-16.
Keep track of what changes. Save the Dyskeratosis Congenita studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWho runs them
Masonic Cancer Center, University of Minnesota (3) · Emory University (2) · National Cancer Institute (NCI) (2) · Boston Children's Hospital (2) · St. Jude Children's Research Hospital (2) · Istituto Giannina Gaslini (1) · National Center for Research Resources (NCRR) (1) · University Hospital Freiburg (1)
Who these studies take
Of the 9 Dyskeratosis Congenita studies recruiting now, 3 (33%) set no upper age limit and 5 (56%) stop at 75 or younger. 9 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 9 (100%) | 9 (100%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 7 (78%) | 7 (78%) |
| 75 | 4 (44%) | 4 (44%) |
| 85 | 4 (44%) | 4 (44%) |
Across all 20 studies, recruiting or not: 55% stop at 75 or younger and 40% at 65; 95% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Sep 25, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- Cancer in Inherited Bone Marrow Failure SyndromesRecruitingNCT000272741 country
- Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic DataRecruitingNCT078777271 country
- Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)RecruitingNCT07628972Phase 11 country
- Nucleoside Therapy in Patients With Telomere Biology DisordersRecruitingNCT06817590Phase 11 country
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT030502681 country
- Investigation of the Genetics of Hematologic DiseasesRecruitingNCT027206791 country
- Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell BoostsAvailableNCT06731036
- Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 21 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow FailuresRecruitingNCT04232085Phase 21 country
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis CongenitaActive, not recruitingNCT01659606Phase 23 countries
- The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary FibrosisTerminatedNCT04638517Phase 21 country
- Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic AnemiaCompletedNCT02162420Not applicable1 country
- Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)CompletedNCT049591881 country
- Bone Marrow Transplant With Abatacept for Non-Malignant DiseasesCompletedNCT01917708Phase 11 country
- Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaTerminatedNCT01001598Phase 1/21 country
- Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAACompletedNCT00455312Phase 2/31 country
- Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01319851Not applicable1 country
- Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to TreatmentCompletedNCT0049907010 countries
- Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure SyndromesCompletedNCT00004787Phase 2